Top stories: Cardiac arrest—Patients at risk
Curtain et al1 performed an analysis of the VALIANT (Valsartan in Acute Myocardial Infarction) and PARADISE-MI (Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) trials to evaluate whether risk of sudden cardiac arrest (SCA) following acute myocardial infarction (MI) has changed over time. Patients recruited to these trials had left ventricular ejection fraction (LVEF) <40% following acute MI. Between 1998 and 2020, SCA rates dropped from 7.4% to 2.6% with comparable median follow-up duration (VALIANT 24.7 months and PARADISE-MI 22 months).